ACTIN Report (research use only)

PATIENT
EXAMPLE-LUNG-01

REPORT DATE
17-Sep-2025

Gender: **Female** | Birth year: **1975** | WHO: **1**

Tumor: **Lung adenocarcinoma** | Lesions: **Liver, Lung** | Stage: **IV**

Clinical summary

Relevant systemic treatment history	**6/2023-1/2025**	**Osimertinib**

Recent molecular results

Hartwig WGS (22-Feb-2025)

Biopsy location	**Lung (purity 50%)**
Molecular tissue of origin prediction	**Lung: Non-small cell: LUAD (98%)**
Tumor mutational load / burden	**TML 160 / TMB 14 mut/Mb**
Microsatellite (in)stability	**Stable**
HR status	**Proficient (0)**
Driver mutations	**EGFR C797S, EGFR L858R, KRAS G12C, KRAS G12D**
Amplified genes	**None**
Deleted genes	**TP53**
Homozygously disrupted genes	**None**
Gene fusions	**MET(exon13)::MET(exon15) fusion**
Virus	**None**

Trial-relevant IHC results

PD-L1	**Score > 50%**

Phase 2/3+ trials in NL that are open and potentially eligible (1 trial)

Trial	Cohort	Molecular	Sites	Warnings
METC 04 TEDR1 (Phase 2)	Lung cancer C797S cohort	EGFR C797S	NKI-AvL	None

Phase 1/2 (or unknown phase) trials in NL that are open and potentially eligible (4 trials)

Trial	Cohort	Molecular	Sites	Warnings
METC 02 KAYRAS (Phase 1/2)	Dose expansion - monotherapy - NSCLC	KRAS G12D, PD-L1 >= 50.0	Erasmus MC	Variant(s) G12D in KRAS but subclonal likelihood of > 50%
METC 01 IEMOEN (Phase 1)	Dose escalation - monotherapy *(no slots)*	None		Has not exhausted SOC (at least platinum doublet remaining)
EGFR-C797S-TRIAL	*EGFR C797S*	*EGFR C797S*	*Elisabeth-TweeSteden Ziekenhuis*	
EGFR-L858R-TRIAL	*EGFR L858R*	*EGFR L858R*	*Elisabeth-TweeSteden Ziekenhuis*	

Trials matched solely on molecular event and tumor type (no clinical data used) are shown in italicized, smaller font.

International trials that are open and potentially eligible (1 trial)

Trial	Cohort	Molecular	Sites
KRAS-G12C-TRIAL-DE	*KRAS G12C*	*KRAS G12C*	*Germany: Stuttgart*

Trials in this table are matched solely on molecular event and tumor type (clinical data excluded).

1 trial filtered due to trials recruiting nationally for the same molecular target. See Other Trial Matching Results for filtered matches.

Molecular Details

Hartwig WGS (EXAMPLE-LUNG-01-T, 22-Feb-2025)

General

Purity	Ploidy	TML Status	TMB Status	MS Stability	HR Status	DPYD	UGT1A1
50%	2.3	**High (160)**	**High (14)**	Stable	Proficient (0)	*1_HOM (Normal function)	*1_HOM (Normal function)

Predicted tumor origin

	1. Lung: Non-small cell: LUAD
Combined prediction score	**98%**
This score is calculated by combining information on:	
(1) SNV types	60%
(2) SNV genomic localisation distribution	70%
(3) Driver genes and passenger characteristics	80%

Other cohorts have a combined prediction of 2% or lower

Key drivers

Type	Driver	Trials (Locations)	Trials in Hartwig	Best evidence in External	Resistance in External
Mutation (gain of function)	EGFR L858R (2/4 copies)		NCT00000006	Approved	
Mutation (gain of function)	EGFR C797S (1/4 copies)	TEDR1 (NKI-AvL)	NCT00000008	Pre-clinical	
Mutation (gain of function)	KRAS G12D (0.3/2 copies)*	KAYRAS (Erasmus MC)			
Mutation (gain of function)	KRAS G12C (0.3/2 copies)*		NCT00000009		
Deletion	TP53 del, 0 copies				
Known fusion	MET(exon13)::MET(exon15) fusion				

* Variant has > 50% likelihood of being sub-clonal

Other drivers or relevant events

Type	Driver	Trials (Locations)	Trials in Hartwig	Best evidence in External	Resistance in External
None					

IHC results

PD-L1	**Score > 50%**

Clinical Details

Clinical summary

Relevant systemic treatment history	**6/2023-1/2025**	**Osimertinib**
Relevant other oncological history	**None**	
Previous primary tumor	**None**	
Relevant non-oncological history	**2023**	**Rheumatoid arthritis**

Patient current details (20-Feb-2025)

Unresolved toxicities grade => 2	**None**
LVEF	**50%**
Known allergies	**None**
Recent surgeries	**01-Aug-2024 Cholecystectomy**

Tumor details (20-Feb-2025)

Measurable disease	**Yes**
Known lesions	**Liver, Lung**
Unknown lesions	**None**
No lesions present	**CNS, Brain, Bone, Lymph node**

Active medication details

Medication	Administration route	Start date	Stop date	Dosage	Frequency
St. John's Wort	Oral	01-Feb-2023		300 MILLIGRAMS	1 / 2 DAYS

Blood transfusions

Product	Date
ERTHROCYTES_FILTERED	20-Sep-2024

Trial Matching Details

Filtered trials potentially eligible based on molecular results which are potentially recruiting (1 trial)

Trial	Cohort	Molecular	Sites
EGFR-BE	*EGFR L858R*	*EGFR L858R*	*Belgium: Brussels*

Trials and cohorts that are potentially eligible, but are closed (1 trial)

Trial	Cohort	Molecular	Sites	Warnings
METC 01 IEMOEN (Phase 1)	Dose expansion - monotherapy	None		Has not exhausted SOC (at least platinum doublet remaining)

Trials and cohorts that are considered ineligible (4 cohorts from 3 trials)

Trial	Cohort	Molecular	Ineligibility reasons
METC 02 KAYRAS (Phase 1/2)	Dose expansion - monotherapy - Colorectum	KRAS G12D, PD-L1 >= 50.0	No colorectal cancer
METC 03 NO-SEE797ES	Dose escalation - monotherapy	EGFR C797S	C797S in EGFR in canonical transcript
METC 05 PICKME3CA	*Applies to all cohorts below*	None	No PIK3CA activating mutation(s)
	Dose expansion - monotherapy - NSCLC *(closed)*		
	Dose expansion - monotherapy - Other cancer types *(closed)*		Tumor belongs to DOID term(s) lung non-small cell carcinoma

Trials and cohorts that are not evaluable or ignored (0 trials)

Trial	Cohort	Molecular	Sites	Configuration
None				